Indication

Recurrent herpes simplex labialis

Recurrent herpes simplex labialis is a chronic, episodic mucocutaneous viral condition characterized by repeated reactivations of herpes simplex virus, predominantly HSV-1 and less commonly HSV-2. Read more about Recurrent herpes simplex labialis

24 drugs 21 manufacturers

Advertisement

Drugs that treat it

Common Recurrent herpes simplex labialis therapies.

Showing 10–18 of 24 drugs

FAMCICLOVIR

ANTIVIRAL - HERPES VIRUSES·HERPES ZOSTER·+4
CAMBER PHARMACE

ACYCLOVIR

RECURRENT HERPES SIMPLEX LABIALIS
L Perrigo Company

ACYCLOVIR

TOPICAL ANTIVIRALS·RECURRENT HERPES SIMPLEX LABIALIS
TEVA USA

FAMCICLOVIR

ANTIVIRAL - HERPES VIRUSES·HERPES ZOSTER·+4
AVKARE
Filter & compare in the drug finder →Opens the drug finder with Recurrent herpes simplex labialis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Recurrent herpes simplex labialis.

Recurrent herpes simplex labialis is a chronic, episodic mucocutaneous viral condition characterized by repeated reactivations of herpes simplex virus, predominantly HSV-1 and less commonly HSV-2.

It affects the perioral tissues and vermilion border of the lips across general pediatric and adult populations who harbor latent infection within sensory ganglia, specifically the trigeminal ganglion.

Following reactivation triggered by physical or emotional stressors, such as ultraviolet light, illness, or immunosuppression, the virus travels anterograde along peripheral sensory axons to the epithelial surface.

Clinically, episodes present with localized prodromal paresthesias—including tingling, burning, or itching—followed by the eruption of painful, clustered vesicles that ulcerate, crust, and spontaneously resolve over seven to ten days.

Personalize your experience

Follow Recurrent herpes simplex labialis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it